Genomic Biomarkers Market by Indication and End User : Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022

  • ID: 4531871
  • Report
  • Region: Global
  • 110 pages
  • Zion Market Research
1 of 4
The report covers forecast and analysis for the genomic biomarkers market on a global and regional level. The study provides historical data from 2014 along with a forecast from 2017 to 2022 based on revenue (USD Billion). The study includes drivers and restraints for the genomic biomarkers market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the genomic biomarkers market on a global as well as regional level.

In order to give the users of this report a comprehensive view on the genomic biomarkers market, we have included competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein indication and end-user segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new product launch, agreements, partnerships, collaborations joint ventures, research development, regional expansion of major participants involved in the market on the global and regional basis.

The study provides a decisive view on the genomic biomarkers market by segmenting the market based on the indication, end user, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2022. Based on the indication, genomic biomarkers market has been segmented into oncology, cardiovascular diseases, neurological diseases and others. Oncology segment holds a maximum share of global genomic biomarkers market.

Based on the end user, genomic biomarkers market is classified into hospitals, diagnostic research laboratories, and others. Diagnostic research laboratories segment dominated the global genomic biomarker market.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and the Middle East Africa with its further bifurcation into major countries including the U.S. Canada, Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for genomic biomarkers based on individual segment and applications in all the regions and countries.

The report also includes detailed profiles of end players such as Thermo Fisher Scientific, Roche Diagnostics, Myriad Genetics, QIAGEN, Bio-Rad Laboratories, US Biomarkers Inc., Almac Group and Epigenomics AG among others.

This report segments the global genomic biomarkers market as follows:

Global Genomic Biomarkers Market: By Indication
Oncology
Cardiovascular diseases
Neurological diseases
Others

Global Genomic Biomarkers Market: By End User
Hospitals
Diagnostic Research Laboratories
Others

Global Genomic biomarkers Market: By Region
North America
U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology

2. Executive Summary
2.1. Global genomic biomarkers market, 2014 2022 (USD Billion)
2.2. Global genomic biomarkers market : Snapshot

3. Genomic Biomarkers Market Dynamics
3.1. Introduction
3.2. Market drivers
3.2.1. Global genomic biomarkers market drivers: Impact analysis
3.2.2. Increasing prevalence of cardiovascular diseases, cancer, neurological disorders across the globe
3.2.3. Rising need for genomic biomarker based personalized medicines
3.3. Market restraints
3.3.1. Global Genomic biomarkers market restraints: Impact analysis
3.3.2. Stringent government regulations
3.4. Opportunities
3.4.1. Increasing adoption of personalized medicines
3.5. Porters five forces analysis
3.5.1. Bargaining power of suppliers
3.5.2. Bargaining power of buyers
3.5.3. Threat from new entrants
3.5.4. Threat from new substitutes
3.5.5. Degree of competition
3.6. Market attractiveness analysis
3.6.1. Market attractiveness analysis, by indication segment
3.6.2. Market attractiveness analysis, by end user segment
3.6.3. Market attractiveness analysis, by regional segment

4. Global Genomic Biomarkers Market Competitive Landscape
4.1. Company Market Share Analysis
4.1.1. Global genomic biomarkers market: company market share, 2015
4.2. Strategic Development
4.2.1. Acquisitions Mergers
4.2.2. New Product Launch
4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
4.2.4. Research and Development, Regional Expansion

5. Global Genomic Biomarkers Market Indication Segment Analysis
5.1. Global genomic biomarkers market: Indication overview
5.1.1. Global genomic biomarkers market revenue share, by Indication, 2016 and 2022
5.2. Oncology
5.2.1. Global genomic biomarkers market for Oncology, 2014 2022 (USD Billion)
5.3. Cardiovascular Diseases
5.3.1. Global genomic biomarkers market for Cardiovascular Diseases, 2014 2022 (USD Billion)
5.4. Neurological Diseases
5.4.1. Global genomic biomarkers market for Neurological Diseases, 2014 2022 (USD Billion)
5.5. Other indications
5.5.1. Global genomic biomarkers market for Other indications, 2014 2022 (USD Billion)

6. Global Genomic Biomarkers Market End User Segment Analysis
6.1. Global genomic biomarkers market: End User overview
6.1.1. Global genomic biomarkers market revenue share, by End User, 2016 and 2022
6.2. Hospitals
6.2.1. Global genomic biomarkers market for hospitals, 2014 2022 (USD Billion)
6.3. Diagnostic Research Laboratories
6.3.1. Global genomic biomarkers market for Diagnostic Research Laboratories, 2014 2022 (USD Billion)
6.4. Other End Users
6.4.1. Global genomic biomarkers market for other end users, 2014 2022 (USD Billion)

7. Global Genomic biomarkers Market Regional Segment Analysis
7.1. Global genomic biomarkers market: Regional overview
7.1.1. Global genomic biomarkers market revenue share, by region, 2016 and 2022
7.2. North America
7.2.1. North America genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.2.2. North America Genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.2.3. U.S.
7.2.3.1. U.S. genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.2.3.2. U.S. genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.2.4. Canada
7.2.4.1. Canada genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.2.4.2. Canada genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.2.5. Rest of North America
7.2.5.1. Rest of North America genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.2.5.2. Rest of North America genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.3. Europe
7.3.1. Europe genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.3.2. Europe genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.3.3. U.K.
7.3.3.1. U.K. genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.3.3.2. U.K. genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.3.4. Germany
7.3.4.1. Germany genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.3.4.2. Germany genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.3.5. France
7.3.5.1. France genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.3.5.2. France genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.3.6. Italy
7.3.6.1. Italy genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.3.6.2. Italy genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.3.7. Spain
7.3.7.1. Spain genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.3.7.2. Spain genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.3.8. Russia
7.3.8.1. Russia genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.3.8.2. Russia genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.3.9. Rest of Europe
7.3.9.1. Rest of Europe genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.3.9.2. Rest of Europe genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.4. Asia Pacific
7.4.1. Asia Pacific Genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.4.2. Asia Pacific Genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.4.3. China
7.4.3.1. China genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.4.3.2. China genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.4.4. Japan
7.4.4.1. Japan genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.4.4.2. Japan genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.4.5. India
7.4.5.1. India genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.4.5.2. India genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.4.6. Australia
7.4.6.1. Australia genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.4.6.2. Australia genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.4.7. Rest of Asia Pacific
7.4.7.1. Rest of Asia Pacific genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.4.7.2. Rest of Asia Pacific genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.5. Latin America
7.5.1. Latin America Genomic biomarkers market revenue, by indication, 2014 2022(USD Billion)
7.5.2. Latin America Genomic biomarkers market revenue, by end user, 2014 2022(USD Billion)
7.5.3. Brazil
7.5.3.1. Brazil genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.5.3.2. Brazil genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.5.4. Mexico
7.5.4.1. Mexico genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.5.4.2. Mexico genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.5.5. Argentina
7.5.5.1. Argentina genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.5.5.2. Argentina genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.5.6. Rest of Latin America
7.5.6.1. Rest of Latin America genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.5.6.2. Rest of Latin America genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.6. Middle East and Africa
7.6.1. Middle East and Africa genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.6.2. Middle East and Africa genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.6.3.2. Saudi Arabia genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.6.4. UAE
7.6.4.1. UAE genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.6.4.2. UAE genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.6.5. South Africa
7.6.5.1. South Africa genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.6.5.2. South Africa genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.6.6. Qatar
7.6.6.1. Qatar genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.6.6.2. Qatar genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)
7.6.7. Rest of Middle East and Africa
7.6.7.1. Rest of Middle East and Africa genomic biomarkers market revenue, by indication, 2014 2022 (USD Billion)
7.6.7.2. Rest of Middle East and Africa genomic biomarkers market revenue, by end user, 2014 2022 (USD Billion)

8. Company Profile
8.1. Thermo Fisher Scientific
8.1.1. Overview
8.1.2. Financials
8.1.3. Therapy portfolio
8.1.4. Business strategy
8.1.5. Recent developments
8.2. Roche Diagnostics
8.2.1. Overview
8.2.2. Financials
8.2.3. Therapy portfolio
8.2.4. Business strategy
8.2.5. Recent developments
8.3. Myriad Genetics
8.3.1. Overview
8.3.2. Financials
8.3.3. Therapy portfolio
8.3.4. Business strategy
8.3.5. Recent developments
8.4. QIAGEN
8.4.1. Overview
8.4.2. Financials
8.4.3. Therapy portfolio
8.4.4. Business strategy
8.4.5. Recent developments
8.5. Bio-Rad Laboratories
8.5.1. Overview
8.5.2. Financials
8.5.3. Therapy portfolio
8.5.4. Business strategy
8.5.5. Recent developments
8.6. US Biomarkers Inc.
8.6.1. Overview
8.6.2. Financials
8.6.3. Therapy portfolio
8.6.4. Business strategy
8.6.5. Recent developments
8.7. Almac Group
8.7.1. Overview
8.7.2. Financials
8.7.3. Therapy portfolio
8.7.4. Business strategy
8.7.5. Recent developments
8.8. Epigenomics AG
8.8.1. Overview
8.8.2. Financials
8.8.3. Therapy portfolio
8.8.4. Business strategy
8.8.5. Recent developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll